Moderate hypofractionation for prostate cancer with fiducials markers
Jessica Guadalupe Molina Osorio,
Spain
PO-1382
Abstract
Moderate hypofractionation for prostate cancer with fiducials markers
Authors: Jessica Guadalupe Molina Osorio1, Gerard Meca Santamaria2, Makarena Villalobos Monardes1, Sara Moreno López1, Rosa Ballester Alabau3, Ana Álvarez Gracia1, Silvia Comas Anton1, Josep Jové Teixido2, Mónica Caro Gallarin2, LLuis Prats Cabeces4, Ernest Luguera Sanchez4, Jaume Molero Savall4, Salvador Villà Freixa5
1Institut Català d'Oncologia, Radiation Oncology, Badalona (Barcelona), Spain; 2Institut Català d'Oncologia. , Radiation Oncology, Badalona (Barcelona), Spain; 3Institut Català d'Oncologia , Radiation Oncology, Badalona (Barcelona), Spain; 4Institut Català d'Oncologia, Medical Physics, Badalona (Barcelona), Spain; 5Institut Català d'Oncologia, Radiation Oncology , Badalona (Barcelona), Spain
Show Affiliations
Hide Affiliations
Purpose or Objective
Hypofractionated
radiotherapy for prostate cancer has become a new gold standard. Otherwise It
has been described that the use of fiducials markers implanted within the
prostate allows significant reduction of PTV margins, and this could be related
with decreased toxicity. The purpose of this study was to analyze toxicity of
moderate hypofractionation with fiducial guide radiotherapy for prostate cancer
patients.
Material and Methods
Between
August 2018 and July 2021, 167 patients with prostate cancer were selected to
receive radiotherapy at dose of 60 Gy in 20 fractions over 4 weeks. Three gold
fiducials markers were implanted within prostate before the treatment planning
procedure. Radiation was delivered using VMAT (Volumetric Modulated Arc
Therapy) technique with 6 MV photon beams. Daily image guide control with CBCT
was performed. Toxicity was evaluated according to the Common Terminology
Criteria for Adverse Events (CTCAE) v5.0.
Results
Patient’s
median age was 74 years (range: 53-89), 3.6% of the patients were classified as
low risk, 42,7% as intermediate risk, 51,8% as high risk and 1.8% were identified
with metastatic disease. No infectious prostatitis after fiducials markers
implementation was found. Acute urinary toxicity G2 was observed in 9.3% of
patients and G3 in 1,24%. Acute gastrointestinal toxicity G2 and G3, were observed
in 18% an 17% of patients respectively. Regarding late toxicity, urinary toxicity
G2 was found in 4,5% of patients and 0,75% showed G3 toxicity. Late
gastrointestinal toxicity G2 was identified in 3% of patients. No G3 toxicity was
recorded.
Conclusion
Moderate
hypofractionated radiotherapy for prostate cancer presented good
gastrointestinal and urinary toxicity profile. Furthermore, it reduces
treatment time and supposes an advantage of time consuming and efficiency.